eligibility_summary
Eligible if CD20+ classic FL (Grade 1–3a) per WHO 5th, stage III–IV or bulky II (≥7 cm), need systemic therapy (GELF), PET-positive disease with ≥1 measurable lesion (nodal >1.5 cm or extranodal >1.0 cm), ECOG 0–2, able to receive standard chemoimmunotherapy and R2, meet protocol labs and comply. Exclude: major surgery within 4 weeks, or active CMV disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, randomized trial in previously untreated follicular lymphoma testing: 1) Epcoritamab (SC), a bispecific T‑cell–engaging antibody (CD3×CD20) that redirects cytotoxic T cells to kill CD20+ B cells, combined with rituximab + lenalidomide (R2), vs 24-week ER2, vs R2 alone, vs investigator’s choice chemoimmunotherapy (G-CHOP or R-CHOP, G‑bendamustine or R‑bendamustine). Mechanisms/types: - Epcoritamab: bispecific antibody, T-cell activation via CD3 and B‑cell targeting via CD20. - Rituximab: anti‑CD20 mAb, ADCC/CDC/apoptosis of B cells. - Obinutuzumab: glycoengineered type II anti‑CD20 mAb, enhanced ADCC/direct cell death. - Lenalidomide: IMiD, binds cereblon, degrades IKZF1/3, boosts T/NK cells, modulates cytokines. - Cyclophosphamide/bendamustine: alkylators (DNA crosslinking). - Doxorubicin: anthracycline, topo II inhibition. - Vincristine: microtubule inhibitor. - Prednisone: glucocorticoid, lympholytic. Targets: CD20+ malignant B cells, T cells (CD3), NK/T effector function, DNA damage pathways, microtubules, topo II.